Can We Re-Engineer the Endocrine Pancreas?

A Citro, HC Ott

Research output: Contribution to journalArticle

Abstract

Purpose of Review: Engineering endocrine pancreatic tissue is an emerging topic in type 1 diabetes with the intent to overcome the current limitation of β cell transplantation. During islet isolation, the vascularized structure and surrounding extracellular matrix (ECM) are completely disrupted. Once implanted, islets slowly engraft and mostly are lost for the initial avascular phase. This review discusses the main building blocks required to engineer the endocrine pancreas: (i) islet niche ECM, (ii) islet niche vascular network, and (iii) new available sources of endocrine cells. Recent Findings: Current approaches include the following: tissue engineering of endocrine grafts by seeding of native or synthetic ECM scaffolds with human islets, vascularization of native or synthetic ECM prior to implantation, vascular functionalization of ECM structures to enhance angiogenesis after implantation, generation of engineered animals as human organ donors, and embryonic and pluripotent stem cell-derived endocrine cells that may be encapsulated or genetically engineered to be immunotolerated. Summary: Substantial technological improvements have been made to regenerate or engineer endocrine pancreatic tissue; however, significant hurdles remain, and more research is needed to develop a technology to integrate all components of viable endocrine tissue for clinical application. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
Original languageEnglish
Article number122
JournalCurrent Diabetes Reports
Volume18
Issue number11
DOIs
Publication statusPublished - 2018

Fingerprint

Islets of Langerhans
Extracellular Matrix
Endocrine Cells
Blood Vessels
Pluripotent Stem Cells
Cell Transplantation
Tissue Engineering
Embryonic Stem Cells
Type 1 Diabetes Mellitus
Tissue Donors
Technology
Transplants
Research

Cite this

Can We Re-Engineer the Endocrine Pancreas? / Citro, A; Ott, HC.

In: Current Diabetes Reports, Vol. 18, No. 11, 122, 2018.

Research output: Contribution to journalArticle

Citro, A ; Ott, HC. / Can We Re-Engineer the Endocrine Pancreas?. In: Current Diabetes Reports. 2018 ; Vol. 18, No. 11.
@article{f3f9a850827d40eb8f2bdc4b0ef36474,
title = "Can We Re-Engineer the Endocrine Pancreas?",
abstract = "Purpose of Review: Engineering endocrine pancreatic tissue is an emerging topic in type 1 diabetes with the intent to overcome the current limitation of β cell transplantation. During islet isolation, the vascularized structure and surrounding extracellular matrix (ECM) are completely disrupted. Once implanted, islets slowly engraft and mostly are lost for the initial avascular phase. This review discusses the main building blocks required to engineer the endocrine pancreas: (i) islet niche ECM, (ii) islet niche vascular network, and (iii) new available sources of endocrine cells. Recent Findings: Current approaches include the following: tissue engineering of endocrine grafts by seeding of native or synthetic ECM scaffolds with human islets, vascularization of native or synthetic ECM prior to implantation, vascular functionalization of ECM structures to enhance angiogenesis after implantation, generation of engineered animals as human organ donors, and embryonic and pluripotent stem cell-derived endocrine cells that may be encapsulated or genetically engineered to be immunotolerated. Summary: Substantial technological improvements have been made to regenerate or engineer endocrine pancreatic tissue; however, significant hurdles remain, and more research is needed to develop a technology to integrate all components of viable endocrine tissue for clinical application. {\circledC} 2018, Springer Science+Business Media, LLC, part of Springer Nature.",
author = "A Citro and HC Ott",
year = "2018",
doi = "10.1007/s11892-018-1072-7",
language = "English",
volume = "18",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "11",

}

TY - JOUR

T1 - Can We Re-Engineer the Endocrine Pancreas?

AU - Citro, A

AU - Ott, HC

PY - 2018

Y1 - 2018

N2 - Purpose of Review: Engineering endocrine pancreatic tissue is an emerging topic in type 1 diabetes with the intent to overcome the current limitation of β cell transplantation. During islet isolation, the vascularized structure and surrounding extracellular matrix (ECM) are completely disrupted. Once implanted, islets slowly engraft and mostly are lost for the initial avascular phase. This review discusses the main building blocks required to engineer the endocrine pancreas: (i) islet niche ECM, (ii) islet niche vascular network, and (iii) new available sources of endocrine cells. Recent Findings: Current approaches include the following: tissue engineering of endocrine grafts by seeding of native or synthetic ECM scaffolds with human islets, vascularization of native or synthetic ECM prior to implantation, vascular functionalization of ECM structures to enhance angiogenesis after implantation, generation of engineered animals as human organ donors, and embryonic and pluripotent stem cell-derived endocrine cells that may be encapsulated or genetically engineered to be immunotolerated. Summary: Substantial technological improvements have been made to regenerate or engineer endocrine pancreatic tissue; however, significant hurdles remain, and more research is needed to develop a technology to integrate all components of viable endocrine tissue for clinical application. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.

AB - Purpose of Review: Engineering endocrine pancreatic tissue is an emerging topic in type 1 diabetes with the intent to overcome the current limitation of β cell transplantation. During islet isolation, the vascularized structure and surrounding extracellular matrix (ECM) are completely disrupted. Once implanted, islets slowly engraft and mostly are lost for the initial avascular phase. This review discusses the main building blocks required to engineer the endocrine pancreas: (i) islet niche ECM, (ii) islet niche vascular network, and (iii) new available sources of endocrine cells. Recent Findings: Current approaches include the following: tissue engineering of endocrine grafts by seeding of native or synthetic ECM scaffolds with human islets, vascularization of native or synthetic ECM prior to implantation, vascular functionalization of ECM structures to enhance angiogenesis after implantation, generation of engineered animals as human organ donors, and embryonic and pluripotent stem cell-derived endocrine cells that may be encapsulated or genetically engineered to be immunotolerated. Summary: Substantial technological improvements have been made to regenerate or engineer endocrine pancreatic tissue; however, significant hurdles remain, and more research is needed to develop a technology to integrate all components of viable endocrine tissue for clinical application. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.

U2 - 10.1007/s11892-018-1072-7

DO - 10.1007/s11892-018-1072-7

M3 - Article

VL - 18

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 11

M1 - 122

ER -